|

ARR-002 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • ArriVent BioPharma, Inc.1

Indications

  • Platinum-resistant Ovarian Cancer (PROC)1
  • Metastatic Endometrial Cancer1
  • Metastatic Ovarian Cancer1
  • Endometrial Cancer1
  • Ovarian Cancer1

Orlando, Florida1 trial

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Sarah Cannon Research Institute at Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.